Navigation Links
So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
Date:11/15/2007

Hoffmann-La Roche Inc. CEO George Abercrombie, Pfizer R&D Head Martin Mackay, HHS Deputy Secretary Tevi Troy, Former CMS Administrator & FDA Commissioner Mark McClellan Headline Agenda at FDA/CMS Summit 2007

WASHINGTON, Nov. 15 /PRNewswire-USNewswire/ -- It's shaping up to be a record year for drug approvals. Unfortunately for the biopharma sector and investors, it's a record low. The Food and Drug Administration is on track to grant marketing approval to 18 or fewer new drugs in 2007, and pipelines are not looking better in the coming years. For the research and development and marketing executives responsible for getting new drugs to customers, the level of unpredictability may be unprecedented. And Washington lawmakers and regulators are driving the uncertainty. Yesterday's blockbuster will not be the prototype for future drug development. Sweeping new legislation is reforming the FDA and changing how drugs are developed; Medicare is radically altering product economics; and Wall Street is looking for the next big thing.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071115/DC07546LOGO )

The FDA/CMS Summit, taking place December 6-7 in Washington, D.C., will feature the key decision makers from government and industry to help biopharmaceutical executives understand what regulatory and policy developments mean for research and commercial success.

"Today may look a lot like yesterday, but the rules of the game have fundamentally changed," said Cole Werble, editor-in-chief of The RPM Report, the lead sponsor of the conference. "Industry needs to learn what recent changes to FDA law mean and what the impact might hold for drug development and marketing. The FDA/CMS Summit provides leaders in industry key insight from policy-makers who have been involved in these changes."

The FDA/CMS Summit provides health care executives with an exclusive oppo
'/>"/>

SOURCE Windhover Information Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Stem Cell Science Holds Opportunities as Important Tool for Diabetes Research Beyond Cell-Based Treatments
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
9. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014   MSC , a healthcare ... today announced the appointment of Mary Beth Loesch ... 28 years of experience preparing companies for rapid growth ... Executive Vice President of Corporate Development and Healthcare. In ... business , as well as corporate strategy and marketing. ...
(Date:8/27/2014)... , Aug. 27, 2014 ... the "Global Lactic Acid  (Biodegradable Polymer, Food ... Trends & Forecasts to 2019" report to ... simplest hydroxyl-carboxylic acid with an asymmetrical carbon atom. ... the biodegradable polymer, food and beverage, personal care ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... of Guggenheim Partners, today announced the hiring of veteran ... and senior equity analyst. Mr. Butler will focus on ... brings our team a wealth of experience and a ... Dante Ferrarie , Senior Managing Director and Head of ...
(Date:8/27/2014)... -- Research and Markets  has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... mass spectrometer industry. The report provides a ... and industry chain structure. The isotope ratio mass spectrometer ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... Repligen Corporation (Nasdaq: RGEN ) today reported results ... Total revenue for the quarter was $5,061,000 compared to total ... The prior year results were favorably impacted by a one-time ... U.S. sales of Orencia(R) prior to the April 2008 patent licensing ...
... , SEATTLE, Aug. 6 Cell Therapeutics, ... financial results for the second quarter and six months ended June ... 2009 was a transforming quarter for the Company as we reported, ... American Society of Clinical Oncology Annual Meeting and completed the submission ...
... To use hydrogen as a clean energy source, some engineers ... compressing the gas into a tank. A gas flows easily ... molecule requires a catalyst. Now, researchers reveal new details about ... catalysts for use in hydrogen energy applications such as fuel ...
Cached Biology Technology:Repligen Reports First Quarter Fiscal Year 2010 Financial Results 2Repligen Reports First Quarter Fiscal Year 2010 Financial Results 3Repligen Reports First Quarter Fiscal Year 2010 Financial Results 4Repligen Reports First Quarter Fiscal Year 2010 Financial Results 5Repligen Reports First Quarter Fiscal Year 2010 Financial Results 6Repligen Reports First Quarter Fiscal Year 2010 Financial Results 7Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 2Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 3Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 4Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 5Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 6Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval 7New clues about a hydrogen fuel catalyst 2New clues about a hydrogen fuel catalyst 3
(Date:8/28/2014)... exports from Washington, Oregon, northern California, and Alaska totaled ... quarter of 2014, an increase of more than 10 ... U.S. Forest Service,s Pacific Northwest Research Station reported today. ... by 4 percent to 247 million board feet. , ... more than 5 percent to $390 million in the ...
(Date:8/27/2014)... Wis. The mechanical force that a single fungal cell ... vanishingly small, but it plays a heavy role in setting ... In fact, it may not be too much of a ... land without the ability to respond to the touch of ... An, a professor of agronomy at the University of Wisconsin-Madison. ...
(Date:8/27/2014)... functional near infrared spectroscopy (fNIRS), Kessler Foundation researchers ... with multiple sclerosis (MS) and healthy controls. This ... activation was studied using fNIRS while participants performed ... using functional near infrared spectroscopy (fNIRS) in multiple ... Brain Imaging and Behavior . Authors are ...
Breaking Biology News(10 mins):West coast log exports up, lumber exports down in second quarter of 2014 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2
... a man with apparent battle wounds and curvature of the ... the University of Leicester. The University of Leicester has ... King Richard III with Leicester City Council, in association with ... third week, has yielded dramatic findings of human remains which ...
... Va., September 12, 2012 Using old deeds and ... a glimpse of the composition of the forests that ... changed the landscape., "European Settlement-Era Vegetation of the Monongahela ... scientist and her West Virginia University colleague answered questions ...
... This release is available in French . ... University of Montreal have identified several novel genes that ... way their immune system responds to malaria infection. This ... to specific immune responses to malaria and ultimately to ...
Cached Biology News:King Richard III search in new phase after 'discovery has potential to rewrite history' 2King Richard III search in new phase after 'discovery has potential to rewrite history' 3King Richard III search in new phase after 'discovery has potential to rewrite history' 4King Richard III search in new phase after 'discovery has potential to rewrite history' 5King Richard III search in new phase after 'discovery has potential to rewrite history' 6King Richard III search in new phase after 'discovery has potential to rewrite history' 7King Richard III search in new phase after 'discovery has potential to rewrite history' 8King Richard III search in new phase after 'discovery has potential to rewrite history' 9Old deeds, witness trees offer glimpse of pre-settlement forest in West Virginia 2Old deeds, witness trees offer glimpse of pre-settlement forest in West Virginia 3Genetic make-up of children explains how they fight malaria infection 2
... c-Jun N-terminal kinase (JNK) is one of ... luciferase has been used as a sensitive ... Luciferase provides a 1000-fold increase in sensitivity ... (CAT) assay. Firefly luciferase catalyzes the oxidative ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: filling ...
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... DMEM and harvested at the log phase of ... in their native forms, cells were fixed in ... 12-well (5 mm) adhesive coated slide, with each ... and to minimize background staining. Each well ...
Biology Products: